About arfolitixorin

ARFOLITIXORIN – A NEW DRUG CANDIDATE FOR  COLORECTAL CANCER

Isofol intends to address the unmet medical need in the advanced colorectal cancer field using its substance, arfolitixorin, in combination with one of the world’s most widely used cancer treatment drugs, 5-FU (5-Fluorouracil).

Arfolitixorin is Isofol’s proprietary drug candidate being developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer. The drug candidate is currently being studied in a global Phase 3 clinical trial. As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit all patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective.

Treating cancer patients with arfolitixorin – The goals:

• When treating colorectal cancer, for example, arfolitixorin is administered in combination with 5-FU to increase cell mortality in circulating cancer cells and in cancerous tumours.
• Arfolitixorin is administered in conjunction with rescue therapy after high-dose treatment with the cytotoxic agent, methotrexate, in order to suppress the cytotoxic effect in surrounding healthy tissue. The treatment is used for certain types of cancer, such as osteosarcoma, a type of bone cancer. This involves administering arfolitixorin separately, 24 hours after the chemotherapy.